The expert in ovarian cancer indicated that treatment with the studied maintenance olaparib tablets could aid patients in having a more regular lifestyle.
Andres Poveda, MD
Advertisement
Articles by Andres Poveda, MD
The results of the trial demonstrated that maintenance olaparib provided an unprecedented improvement in median OS versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Final overall survival results from the trial showed that maintenance olaparib provided an unprecedented improvement in median overall survival versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Advertisement
Latest Updated Articles
Andres Poveda, MD, on the Phase III SOLO2/ENGOT-ov21 Final OS Data in Ovarian CancerPublished: June 4th 2020 | Updated:
Phase 3 SOLO2/ENGOT-ov21 Trial Shows Promise for Maintenance Olaparib in Ovarian CancerPublished: June 29th 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
2
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
3
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
